It has been shown that melatonin, as an activator of Nrf2, can inhibit NLRP3 inflammation, reduce atherosclerosis, and improve cerebral ischemia–reperfusion injury by activating Nrf2 [48,49]. The gene discussed is NLRP3; the disease is atherosclerosis.